This phase II trial is comparing alternating chemotherapy and standard of care for patients whose colorectal cancer has spread to other parts of the body.
This trial is treating patients with colorectal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial
Other Non-Commercial Sponsor
Walter and Eliza Hall Institute
Patients will be randomly allocated to receive an alternating schedule of oxiplatin based chemotherapy and irinotecan based chemotherapy, OR a chemotherapy that has been selected by the treating clinician. All patients will receive combination chemotherapy for 4-6 months followed by a maintenance period.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More